Ozmosi | Vincristine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Vincristine

Alternative Names: vincristine, vincristina, marqibo, oncovin, Vincristine Sulfate, vincristin, vincasar pfs, vincrex
Clinical Status: Inactive
Latest Update: 2026-03-11
Latest Update Note: Clinical Trial Update

Product Description

Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)

Mechanisms of Action: Mitosis Inhibitor, Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Premier Inc
Company Location:
Company Founding Year: None
Additional Commercial Interests: Pfizer

Clinical Description

Map of Global Clinical Trials for Vincristine

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 27

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Lymphoma|Lymphoma, B-Cell|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Retinoblastoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma

Phase 2: Burkitt Lymphoma|COVID-19|Desmoplastic Small Round Cell Tumor|Fetal Diseases|Follicular Lymphoma|Lymphoproliferative Disorders|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Small Cell Sarcoma|T-Cell Leukemia

Phase 1: Lymphoma, Non-Hodgkin

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03467373

NP40126

P1

Completed

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2024-12-02

41%

2025-01-18

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT05848765

REFRACT

P2

Recruiting

Follicular Lymphoma

2029-05-31

78%

2024-11-27

NCT06709495

NCT06709495

P2

Recruiting

Sarcoma, Ewing|Osteosarcoma|Primitive Neuroectodermal Tumors|Small Cell Sarcoma|Desmoplastic Small Round Cell Tumor|Rhabdomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive

2028-11-01

12%

2025-02-14

NCT06738368

RG1124788

P2

Recruiting

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Burkitt Lymphoma|Acute Lymphoid Leukemia

2028-01-31

12%

2026-01-31

NCT06954805

AAAV2404

P2

Recruiting

Lymphoma, B-Cell|Lymphoproliferative Disorders

2027-04-14

2025-05-03

Primary Endpoints|Treatments

NCT04980222

GO43075

P2

Active, not recruiting

Lymphoma

2026-09-30

12%

2025-11-19

Primary Completion Date|Primary Endpoints|Treatments

NCT05280626

CIBI308Y047

P2

Not yet recruiting

Diffuse Large B-Cell Lymphoma

2025-12-31

54%

2024-11-27

Primary Endpoints|Treatments

ACTRN12622000173796p

SBSDS

P2

Not yet recruiting

Pregnancy Outcomes|Fetal Diseases|Pregnancy Complications, Infectious|COVID-19

2022-12-31

NCT04681417

RETINO2018

P3

Recruiting

Retinoblastoma

2035-01-20

2024-11-27

Primary Endpoints|Treatments

NCT06072131

CRESCENDO

P3

Recruiting

T-Cell Peripheral Lymphoma

2030-07-01

18%

2024-11-27

2018-003335-29

2018-003335-29

P3

Active, not recruiting

Other

2029-10-15

2022-03-13

Treatments

NCT03117751

TOT17

P3

Active, not recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-09-30

10%

2024-11-27

Primary Endpoints|Treatments

NCT02684708

EuroNet-PHL-C2

P3

Active, not recruiting

Hodgkin Lymphoma

2026-09-30

2021-05-14

Primary Endpoints|Treatments|Trial Status

2012-000793-30

IntReALL SR 2010

P3

Completed

Acute Lymphoid Leukemia

2024-04-25

2025-05-06

Treatments

NCT01478542

OPTIMAL>60

P3

Completed

Lymphoma, B-Cell

2024-01-18

74%

2024-04-27

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04231448

DEB

P3

Active, not recruiting

Diffuse Large B-Cell Lymphoma

2023-01-10

37%

2024-12-06

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

CTR20192684

CTR20192684

P3

Completed

Diffuse Large B-Cell Lymphoma

2025-06-29

2025-11-02

NCT04307576

ALLTogether1

P3

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2033-06-01

59%

2025-08-29

NCT06947967

SWIFT 02

P3

Recruiting

T-Cell Peripheral Lymphoma

2032-12-01

33%

2025-09-16

Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status

2019-004153-93

2019-004153-93

P3

Active, not recruiting

Sarcoma, Ewing

2030-12-17

2025-06-19

Treatments

NCT06533748

SJALL23H

P2

Recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2028-05-01

12%

2025-01-11

NCT03755804

cHOD17

P2

Active, not recruiting

Hodgkin Lymphoma

2027-01-01

12%

2025-09-23

NCT02866136

RETINO2011

P2

Active, not recruiting

Retinoblastoma

2023-01-01

2024-11-27

Primary Endpoints|Treatments

NCT06356129

GOLSEEK-1

P3

Active, not recruiting

Lymphoma, B-Cell

2028-08-14

27%

2026-02-13

Primary Endpoints|Trial Status

NCT03020030

NCT03020030

P3

Active, not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2026-11-30

40%

2025-01-04